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INTRODUCTION
Human milk oligosaccharides generally represent 
a large proportion of the total solids with components. 
Human colostrum and mature milk contain 22–24 g/l 
and 12–13 g/l of oligosaccharides, respectively; this oligo-
saccharide fraction is the third largest solid components, 
after lactose and lipid (Newburg & Neubauer, 1995). The 
oligosaccharide content of human milk is about 20-fold 
higher than that of bovine milk and is even higher than 
that of bovine colostrum (Veh et al., 1981; Nakamura et 
al., 1998). Human milk is also considered to be unique 
in its high content of complex fucosylated and sialylated 
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ABSTRACT
The percentage of carbohydrate in the milk/colostrum of the mammalian is range from trace to 
over 10%, of which disaccharide lactose (Gal(β1-4)Glc) is usually constitutes the major part. Apart 
from the lactose (Gal(β1-4)Glc; Gal, D-galactose; Glc, D-glucose), the rest of carbohydrate components 
is composed of variety of sugars, commonly named as milk oligosaccharides. Human mature milk 
and colostrum contain 12 ~ 13 g/l and 22 ~ 24 g/l of oligosaccharides, respectively. In contrast, bovine 
colostrum contains more than 1 g/l oligosaccharides and this concentration rapidly decreases after 
48 hr post partum. Most of human milk oligosaccharides (HMO) are resistant to digestion and 
absorption within the small intestine. Therefore they can reach the infant colon, where they can 
act as prebiotics that stimulate the growth of beneﬁ cial microorganisms such as various species of 
Biﬁ dobacterium. They can also act as receptor analogues that inhibit the aĴ achment of pathogenic 
microorganisms to the infant’s colonic mucosa. A small part of the milk oligosaccharides is absorbed 
intact into the circulation and it has been hypothesized that these may act as immunomodulators. 
Generally, the bovine milk oligosaccharides are believed not to be absorbed by human adults 
or infants, thus making them available to be utilized as prebiotics or anti-infection materials. The 
colostrum of cows and other domestic farm animals is a potential source of free oligosaccharides, and 
oligosaccharides isolated from these natural sources can be utilized as functional foods or animal 
feedstuﬀ s on the industrial scale.
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oligosaccharides (Kunz et al., 1999). In this review, we 
will introduce the structural feature of human milk 
oligosaccharides, on their fate within the gastrointestinal 
tract as well as on their possible biological functions as 
prebiotics, anti infection agents and immunomodulation 
factors. In addition, we will discuss the possibility of the 
commercial utilization of bovine milk oligosaccharides 
and those of other domestic farm animals.
THE CHEMICAL STRUCTURES AND THEIR 
QUANTITATIVE ASPECTS OF HUMAN 
MILK OLIGOSACCHARIDES
The structures of at least 115 human milk oligo-
saccharides (HMOs) have been determined to date 
(Urashima et al., in press), while as many as 200 diﬀ erent 
oligosaccharides have been separated and studied by 
microﬂ uidic high performance liquid chromatography 
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(HPLC) – chip mass spectrometry (MS) (Ninonuevo 
et al., 2006). The 115 human milk oligosaccharides, the 
structures of which have been determined to date, can 
be grouped into 13 series based on their core units as in 
Table 1 (Urashima et al., in press). The many variations 
of the oligosaccharides are constructed by the addition 
of a Neu5Acα2-3/2-6 residue to Gal or GlcNAc, and of 
Fucα1-2/1-3/1-4 to Gal, GlcNAc or a reducing Glc of the 
core units.
The main structural features of human milk oligo-
saccharides are the presence of oligosaccharides contain-
ing the type I unit (Gal(β1-3)GlcNAc), as well as those 
containing the type II unit (Gal(β1-4)GlcNAc). The milk 
oligosaccharides of other species mostly have the type II 
but not the type I unit (Urashima et al., 2001; Urashima et 
al., 2007). The many varieties of oligosaccharides in hu-
man milk and colostrum are produced by the addition 
of Neu5Ac and/or Fuc residues to these two units.
The great variety of oligosaccharides in human 
milk depends on the activity of many diﬀ erent spe-
ciﬁ c enzymes in the lactating gland (Urashima et al., 
in press). For example, a α1-2-fucosyltransferase is 
expressed in about 77% of all Caucasian women; these 
are classiﬁ ed as secretors. Therefore, the oligosaccha-
rides in the milk from these women are characterized 
by the presence of α1-2-fucosylated components, e.g., 
Gal( 1-4)Glc
Gal( 1-3)GlcNAc( 1-3)Gal( 1-4)Glc
Gal( 1-4)GlcNAc( 1-3)Gal( 1-4)Glc
Gal( 1-4)GlcNAc( 1-6)
Gal( 1-3)GlcNAc( 1-3)
Gal( 1-4)Glc
Gal( 1-4)GlcNAc( 1-6)
Gal( 1-4)GlcNAc( 1-3)
Gal( 1-4)Glc
Gal( 1-3)GlcNAc( 1-3)Gal( 1-4)GlcNAc( 1-3)Gal( 1-4)Glc
Gal( 1-4)GlcNAc( 1-3)Gal( 1-4)GlcNAc( 1-3)Gal( 1-4)Glc
Gal( 1-4)GlcNAc( 1-3)Gal( 1-4)GlcNAc( 1-6)
Gal( 1-3)GlcNAc( 1-3)
Gal( 1-4)Glc
Gal( 1-4)GlcNAc( 1-3)
Gal( 1-3)GlcNAc( 1-3)Gal( 1-4)GlcNAc( 1-6)
Gal( 1-4)Glc
Gal( 1-3)GlcNAc( 1-3)Gal( 1-4)GlcNAc( 1-6)
Gal( 1-3)GlcNAc( 1-3)
Gal( 1-4)Glc
Gal( 1-3)GlcNAc( 1-3)Gal( 1-4)GlcNAc( 1-3)Gal( 1-4)GlcNAc( 1-3)Gal( 1-4)Glc
Lactose
Lacto-N-tetraose
Lacto-N-neotetraose
Lacto-N-hexaose
Lacto-N-neohexaose
para-Lacto-N-hexaose
para-Lacto-N-neohexaose
Lacto-N-octaose
Lacto-N-neooctaose
iso-Lacto-N-octaose
para-Lacto-N-octaose
Gal( 1-4)Glc
Gal( 1-4)GlcNAc( 1-6)
Gal( 1-3)GlcNAc( 1-3)
Gal( 1-4)GlcNAc( 1-6)
Gal( 1-3)GlcNAc( 1-3)
Lacto-N-decaose
Gal( 1-4)GlcNAc( 1-6)
Gal( 1-3)GlcNAc( 1-3)
Gal( 1-4)Glc
Gal( 1-4)GlcNAc( 1-6)
Gal( 1-4)GlcNAc( 1-3)
Lacto-N-neodecaose
Structures Name
Table 1.  The 13 core structures of human milk oligosaccharides
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Fuc(α1-2)Gal(β1-4)Glc (2’-fucosyllactose: 2’-FL), Fuc(α1-
2)Gal(β1-3)GlcNAc(β1-3)Gal(β1-4)Glc(lacto-N-fucopen-
taose I : LNFP I), or more complex oligosaccharides, 
all possessing Fuc(α1-2)Gal(β1-3)GlcNAc residues. 
In the mammary glands of Lewis (a+b-) individuals, 
who produce nonsecretor milk, this enzyme activity is 
absent; as a result, the major fucosylated oligosaccha-
ride is Gal(β1-3)[Fuc(α1-4)]GlcNAc(β1-3)Gal(β1-4)Glc 
(lacto-N-fucopentaose II : LNFP II). This paĴ ern of HMO 
is found in about 20% of the population. In about 5% of 
the population who belong to blood group Lewis (a-b-), 
LNFP II is absent from the milk because of the absence 
of α1-4-fucosyltransferase activity (Urashima et al., in 
press). 
The studies on the quantiﬁ cation of each of the 
oligosaccharides, in terms of their concentration in hu-
man colostrum and mature milk, have only recently 
been undertaken. Milk oligosaccharides can be quanti-
ﬁ ed using reverse – phase or normal – phase HPLC 
subsequent to pre- or post – column labeling techniques. 
Derivatizations are often performed by condensation 
with 2-aminopyridine (PA) (Asakuma et al., 2008), 
1-methyl-3-phenyl-5-pyrazolone (PMP) (Asakuma et 
al., 2007, 2008), anthranilic acid (Leo et al., 2009, 2010), 
or benzoic anhydride (Chaturvedi et al., 2001) to the 
reducing end of the sugar aldehyde. They can also be 
quantiﬁ ed by high pH anion exchange chromatography 
(HPEAC-PAD) without derivatization (Thurl et al., 1996; 
Coppa et al., 1999; Kunz et al., 1996). Sialyl oligosaccha-
rides can be quantiﬁ ed by capillary electrophoresis using 
phosphate buﬀ er containing sodium dodesyl sulfoxide 
(SDS) (Shen et al., 2000; Bao et al., 2007).
When the concentrations of representative neu-
tral HMO including 2’-FL, Gal(β1-4)[Fuc(α1-3)]Glc 
(3-FL), LDFT, LNT, LNnT, LNFP-I, LNFP-II, LNFP-
III, LNDFH-I or LNDFH-II and of representative 
acidic HMO including Neu5Ac(α2-6)Gal(β1-4)Glc 
(6’-SL), Neu5Ac(α2-3)Gal(β1-4)Glc (3’-SL), Neu5Ac(α2-
3)Gal(β1-3)GlcNAc(β1-3)Gal(β1-4)Glc (LST-a), Gal(β1-
3)[Neu5Ac(α2-6)]GlcNAc(β1-3)Gal(β1-4)Glc(LST-b), 
Neu5Ac(α2-6)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (LST-
c), Neu5Ac(α2-3)Gal(β1-3)[Neu5Ac(α2-6)]GlcNAc(β1-
3)Gal(β1-4)Glc (DSLNT), Fuc(α1-2)Gal(β1-3)[Neu5Ac(α2-
6)]GlcNAc(β1-3)Gal(β1-4)Glc(sLNFP-I) and Neu5Ac 
(α2-3)Gal(β1-3)[Fuc(α1-4)]GlcNAc(β1-3)Gal(β1-4)Glc 
(sLNFP-II) were quantiﬁ ed in the colostra of Japanese 
women, the predominant oligosaccharides were shown 
to be 2’-FL, LNFP-I, LNDFH-I and LNT, in that order 
(Asakuma et al., 2007, 2008). Assuming that the total 
oligosaccharide concentration in colostrum was 22~24 
g/l (Newburg & Neubauer, 1995), then these four 
oligosaccharides can be calculated to constitute 25% to 
33% of the total. It has been shown that the above four 
HMO are also predominant oligosaccharides in human 
mature milk (Chaturvedi et al., 2001; Thurl et al., 1996). 
The concentrations of each of the acidic oligosaccharides 
in colostra or in mature milk were lower than those of 
the four neutral oligosaccharides; the most predominant 
acidic oligosaccharide was LST-c, followed by DSLNT, 
6’-SL, 3’-SL and LST-a in that order (Thurl et al., 1996).
It is notable that three/fourth of the prominent 
oligosaccharides in human milk or colostra are of type I, 
which contain Gal(β1-3)GlcNAc (lacto-N-biose I) at their 
non-reducing termini (Asakuma et al., 2008). The con-
centration of LNT, a type I oligosaccharide, was found 
to be 3 to 4 times higher than that of LNnT, which is a 
type II oligosaccharide containing the Gal(β1-4)GlcNAc 
(N-acetyllactosamine) group at its non-reducing termi-
nus (Asakuma et al., 2008). Urashima et al. (2001, 2007) 
have been characterizing the milk oligosaccharides of 
many mammalian species; they have found that the 
milk or colostra of most of these species contain only 
type II oligosaccharides, notable exceptions being chim-
panzee, bonobo and orangutan whose milk or colostrum 
contains both types I and II. However, type II oligosac-
charides predominate over type I in the milk or colostra 
of these apes (Urashima et al., 2009), suggesting that the 
predominance of type I milk oligosaccharides is a char-
acteristic feature of human milk. 
DIGESTION AND ABSORPTION OF 
MILK OLIGOSACCHARIDES IN THE 
GASTROINTESTINAL TRACT
When infants consume milk, the free lactose therein 
is split into galactose and glucose by intestinal lactase 
(neutral β-galactosidase, lactose phlorizin hydrolase), an 
enzyme that is located in the membrane of the microvilli 
of the brush border of the small intestine. The two 
monosaccharides are transported into the enterocytes by 
a speciﬁ c mechanism, whereupon the glucose enters the 
circulation and is used as an energy source while most 
of the galactose is converted to glucose in the liver, to be 
used as an energy source as well.
Much less is known about the exact metabolic fate 
of human milk oligosaccharides. They are resistant to en-
zymatic hydrolysis by the intestinal lactase of the brush 
border (Engfer et al., 2000), and there is evidence that the 
major part of oligosaccharides passes through the small 
intestine without degradation and enters the colon, 
where they are fermented by colonic bacteria (Brand-
Miller et al., 1998; Newburg, 2000). Evidently, the brush 
border of the small intestine does not contain enzymes, 
such as sialidase, fucosidase or N-acetylhexosaminidase 
that can remove sialic acid, fucose, N-acetylglucosamine 
residues, respectively, from the lactose or other core 
units of the milk oligosaccharides. A small fraction of 
human milk oligosaccharides is absorbed intact, perhaps 
by receptor-mediated endocytosis (Gnoth et al., 2001), 
some of which are excreted in the urine. It is unclear 
what proportion and exactly which of the consumed 
milk oligosaccharides are absorbed, but there is an evi-
dence suggesting that circulating oligosaccharides may 
have immunological eﬀ ects on endothelial cells (Rudloﬀ  
et al., 1996).
BIOLOGICAL SIGNIFICANCES OF HUMAN 
MILK OLIGOSACCHARIDES
Biﬁ dobacterium Growth Stimulation
 
Biﬁ dobacteria constitute around 95% to 99.9% of the 
total colonic microﬂ ora within one week after birth in 
breast fed infants. This proportion is lower in the ﬂ ora of 
Vol. 33 No. 3 OLIGOSACCHARIDES IN MILK
192     Edisi Desember 2010
boĴ le fed infants even when prebiotic oligosaccharides 
such as lactulose, galacto oligosaccharides or fructo 
oligosaccharides are present in the milk replacer (Rotimi 
& Duerden, 1981; Benno & Mitsuoka, 1986). It was 
suggested that milk components stimulate the growth 
of colonic biﬁ dobacteria. As mentioned above, human 
milk oligosaccharides are believed to act as prebiotics 
that stimulate the growth of biﬁ dobacteria in the lower 
intestine; this reduces the colonic pH, which would tend 
to inhibit the growth of pathogenic bacteria such as E. 
coli. 
Which of the more than 100 diﬀ erent human 
milk oligosaccharides do stimulate the growth of the 
infant’s colonic biﬁ dobacteria? Kitaoka et al. (2005) have 
proposed that milk oligosaccharides which contain 
lacto-N-biose I (LNB, Gal(β1-3)GlcNAc) are preferential 
growth factors for some species of Biﬁ dobacterium. 
This hypothesis is based on the published genome 
information relating to biﬁ dobacteria and the cloning 
of glycohydrolases, a glycophosphorylase and an ABC 
transporter from a strain of B. longum. The hypothesis 
was initially based on the discovery of an enzyme, in cell 
extracts of B. biﬁ dum, that phosphorolyses lacto-N-biose, 
the products being galactose-1-phosphate and N-acetyl-
glucosamine (Derensy-Dron et al., 1999): this enzyme 
was subsequently puriﬁ ed, and its gene, lnp A, from B. 
longum was cloned (Kitaoka et al., 2005). The lnp A gene 
was found to be located in a novel operon for galactose 
metabolism which also includes genes for a mucin desul-
fatase and for Gal-1-P uridyl transferase and UDP-Glc-4-
epimerase as well as a gene for an ATP-binding casseĴ e 
sugar transporter (Kitaoka et al., 2005). In addition it was 
demonstrated that lacto-N-biose phosphorylase can also 
utilise galacto-N-biose (GNB, Gal(β1-3)GalNAc), which 
is a mucin core unit, as a substrate, but not N-acetyl-
lactosamine (LacNAc, Gal(β1-4)GlcNAc) (Kitaoka et al., 
2005).
The high content and increase in the concentrations 
of LNB containing oligosaccharides such as LNT, LNFP I 
and LNDFH I in early stage milk/colostrum could aﬀ ect 
the formation of biﬁ dus ﬂ ora in the infant colon signiﬁ -
cantly. The metabolism of LNFP I, which is a dominant 
human milk oligosaccharide, by B. biﬁ dum JCM1254 was 
clariﬁ ed by the cloning of an α-fucosidase (Katayama et 
al., 2004), which catalyses the release of non reducing 
fucose from LNFP I, and a lacto-N-biosidase (Wada 
et al., 2008), which catalyses the hydrolysis of LNT to 
produce LNB and lactose, and by the puriﬁ cation and 
crystallization of an ABC type transporter (Suzuki et al., 
2008) which delivers LNB through the cell membrane. 
Since lacto-N-biose phosphorylase was puriﬁ ed from 
an extract of this biﬁ dobacterial strain, it has been sug-
gested that its α-fucosidase produces LNT from LNFP 
I, while its lacto-N-biosidase liberates LNB from LNT, 
which is followed by the uptake of LNB through the cell 
membrane, the LNB is then metabolized to galactose-1-
phosphate and N-acetylglucosamine. A possible meta-
bolic pathway for the N-acetylglucosamine, produced 
from LNFP I or LNT (see above) is suggested, based on 
the analysis of gene products of the galactose operon of 
B. longum ssp. longum NCC2705; N-acetylglucosamine is 
converted to N-acetylglucosamine-1-phosphate by the 
novel enzyme N-acetylhexosamine 1-kinase and then 
to UDP-N-acetylglucosamine by UDP-glucose hexose 
1-phosphate uridyltransferase, ﬁ nally entering the meta-
bolic pathway of amino sugars (Nishimoto & Kitaoka, 
2007). 
On the other hand, growth tests with B. longum ssp 
infantis ATCC 15697, B. longum ssp. longum ATCC 15707, 
B. adolescentis ATCC 15703, B. breve ATCC 27539 or B. 
biﬁ dum ATCC 29521 were performed using a medium 
containing 1% human milk oligosaccharides but no 
lactose, which was incubated at 37˚C for 350 hr (Ward 
et al., 2007). This resulted in a cell density of B. longum 
ssp. infantis strains that was three times higher than that 
of other strains. When oligosaccharide and monosac-
charide proﬁ les in the medium containing human milk 
oligosaccharides were studied using high performance 
thin layer chromatography, a clear change was observed 
after incubation with B. longum ssp. infantis, when com-
pared with the control, which was the medium with no 
inoculation. This change was not found in the medium 
after incubation with B. breve and adolenscentis. These re-
sults showed that B. longum ssp. infantis is able to grow 
with human milk oligosaccharides as the only carbon 
source.
The degradation of human milk oligosaccharides 
was studied during the growth of B. longum ssp. infantis 
ATCC15697, B. breve ATCC15700 or B. longum ssp. lon-
gum DJO010A in broth containing oligosaccharides but 
no lactose by observation of the molecular mass of ions 
in FTICR-MS (LoCascio et al., 2007). In this work, tri to 
heptasaccharides were completely degraded during the 
growth of B. longum ssp. infantis ATCC 15697 over 25 
and 50 hr of incubation, while higher oligosaccharides 
were partially degraded.
The genome of B. longum ssp. infantis ATCC15697 
was fully sequenced to permit investigations into the 
genetic basis and molecular mechanisms underlying 
this phenotype. Many of its genomic features encode 
enzymes that are active on human milk oligosaccharides 
and include a novel 43 kbp region dedicated to oligosac-
charide utilization (Sela et al., 2008). Subsequent bio-
chemical and molecular characterization of human milk 
oligosaccharide – related glycosidases and transport 
proteins have further resolved the mechanism by which 
this strain imports and catabolizes milk oligosaccha-
rides. The glycosidases were identiﬁ ed to be sialidase, 
fucosidase, β-galactosidase, β-hexosaminidase and LNB 
phosphorylase, but lacto-N-biosidase was not found. 
This approach suggested the existence of a pathway 
for the metabolism of milk oligosaccharides in which 
they are transported into the biﬁ dobacterial cell and 
then degraded from the non-reducing end by the above 
glycosidases. 
Anti-pathogenic Agents
It is assumed that HMOs are synthesized by the 
actions of several glycosyltransferases, which usually 
catalyze the biosynthesis of carbohydrate moieties of 
glycoproteins and glycolipids. Therefore it is thought 
that the structures of the non-reducing ends of HMO 
are similar to those of the non-reducing ends of the 
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sugar chains of glycoconjugates, which are found on the 
surface of epithelial cells. It was known that infection by 
many bacteria and viruses starts by binding to particular 
sugar chains of glycoconjugates on the surface of cells of 
the mucous epithelium of the digestive and respiratory 
tracts. Therefore, human milk oligosaccharides might be 
useful for elucidating the structures of the sugar chains 
on the surface of epithelial cells that are the targets of 
speciﬁ c bacteria or viruses.
Ruiz-Palacios et al. (2003) found that HMO contain-
ing Fuc(α1-2)Gal(β1-4)GlcNAc (H-2 antigen epitope) 
at their non-reducing termini inhibit the aĴ achment 
of Campylobacter jejuni to colonic epithelial cells. This 
organism causes diarrhea and paralysis of motor nerves 
in infants. A universal correlation has been observed 
between the breast milk concentration of 2’-FL, which is 
usually the most prominent oligosaccharide in secretor 
donor’s milk, and the frequency of diarrhea in breast 
fed infants, supporting the view that 2’-FL reduces the 
pathogenicity of C. jejuni. 
An interaction of Helicobacter pylori with sialylated 
glycans has been reported. H. pylori is a Gram-negative 
bacterium, resides in the gastric mucosa and adheres 
to the epithelial cells lining the stomach. This organ-
ism infects around 50% of the world population, with 
a higher incidence in developing countries. H. pylori is 
associated with the development of peptic ulcers, mu-
cosa-associated lymphoid-tissue (MALT) lymphoma 
and gastric adenocarcinoma. The preferred interaction 
is with α3-linked sialic acid; glycans having α6-linked 
Neu5Ac are non-binding. For example, 50% inhibition 
by H. pylori of hemagglutination of human erythrocytes 
was observed at a low concentration of some sialylated 
saccharides. The data showed that S-3 PG (Neu5Ac(α2-
3)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc-Cer), Neu5Ac(α2-
3)Gal(β1-4)[Fuc(α1-3)]GlcNAc, 3’-N-acetylneuraminyl-
N-acetyllactosamine (Neu5Ac(α2-3)Gal(β1-4)GlcNAc) 
as well as 3-N-acetylneuraminyl-lacto-N-neotetraose 
(Neu5Ac(α2-3)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc) all 
bound to H. pylori CCUG17874 at similar strength. 3’-SL 
also bound to this organism but its binding ability was 
somewhat weaker than that of the above saccharides. It 
has also been reported that LST a, a human milk oligo-
saccharide, was able to bind to another strain, H. pylori 
J99 (Johansson et al., 2005).
The binding of 3’-SL to H. pylori CCUG17874 is 
noteworthy because this saccharide is found in human 
milk and bovine colostrum. Asakuma et al. (2007) found 
that at the start of lactation the concentration of 3’-SL in 
human colostrum was 360 mg/L, similar to that of 6’-SL. 
However, the concentration of 3’-SL decreased during 
the subsequent two days of lactation, whereas that of 
6’-SL did not. This suggests that, very early stage in lac-
tation, 3’-SL may be more signiﬁ cant in the prevention 
of transmission of H. pylori from mother to infant than 
later on.
Recent studies on the ability of various fractions of 
human milk oligosaccharides to inhibit the adhesion of 
three intestinal microorganisms (enteropathogenic E. 
coli serotype 0119, Vibrio cholerae and Salmonella fyris) to 
diﬀ erentiated Caco-2 cells have shown that the acidic 
fraction had an anti-adhesive eﬀ ect on all three patho-
genic strains. The neutral high molecular weight fraction 
signiﬁ cantly inhibited the adhesion of E. coli 0119 and V. 
cholerae, but not that of S. fyris; the neutral low molecular 
weight fraction was eﬀ ective toward E. coli 0119 and S. 
fyris but not V. cholerae (Coppa et al., 2006). This demon-
strated that human milk oligosaccharides inhibit the ad-
hesion to epithelial cells not only of common pathogens 
such as E. coli but also of other aggressive bacteria such 
as V. cholerae and S. fyris. Thus, oligosaccharides may be 
important factors in human milk that defend against 
acute diarrhea in breast-fed infants.
Furthermore, it has been reported that the human 
milk oligosaccharides fraction, at a concentration of 0.5 
g/L, reduced the binding of the HIV-1 envelope glyco-
protein gp120 to dendritic cell – speciﬁ c ICAM3 – grab-
bing non – integrin (DC-SIGN) in human dendritic cells 
by more than 60%. In addition, the binding of gp120 to 
Raji cells, which expressed DC-SIGN, was reduced by 
more than 60%. It is worth noting that mother to child 
transmission accounts for more than 40% of all HIV-1 
infections in children, with breast-feeding being the 
predominant postnatal transmission route, especially in 
developing countries. However, a majority of breast-fed 
infants born to HIV-positive mothers remain uninfected 
despite continuous exposure to the virus over many 
months. Viral entry across the infant’s mucosal barrier 
is partially mediated by binding of gp120 to DC-SIGN 
on human dendritic cells (DC). It has been hypothesized 
that human milk oligosaccharides, when they reach DC 
in the colon, bind to DC-SIGN and inhibit the transfer of 
HIV to CD4 + T lymphocytes. It has also been suggested 
that this inhibition of HIV-gp120 binding to DC-SIGN 
is caused by oligosaccharides carrying multiple Lewis 
epitopes (Hong et al., 2009). 
Immuno – modulating Eﬀ ect
It is thought that the immuno – modulating eﬀ ect 
of human milk oligosaccharides in infants is acquired 
while the oligosaccharides are circulating after their 
absorption, or by immuno stimulation in the colon 
produced by growth-stimulated beneﬁ cial bacteria. 
Although unequivocal detection of human milk oli-
gosaccharides in the blood of infants has not yet been 
reported (Bode, 2006), it nevertheless seems very likely 
on the basis of their observed urinary excretion (Rudloﬀ  
et al., 1996; Obermeier et al., 1999) that small amounts of 
intact milk oligosaccharides are normally absorbed from 
the gastrointestinal tract, and that they are transported 
into the systemic circulation. 
It follows that they may alter protein-carbohydrate 
interactions also at a systemic level. For example, recent 
studies suggest that human milk oligosaccharides 
interfere with the adhesion of neutrophils to vascular 
endothelial cells (Klein et al., 2000) and platelets (Bode et 
al., 2004). These eﬀ ects appear to be based on the struc-
tural resemblance of some human milk oligosaccharides 
to the glycoprotein ligands of selectins. Selectins are 
trans-membrane proteins that are involved in cell-cell 
interactions in the immune system. P-selectin mediates 
leukocyte deceleration (rolling) on activated endothelial 
cells and initiates leukocyte extravasation at sites of in-
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ﬂ ammation. P-selectin is also involved in the formation 
of platelet-neutrophil complexes (PNC), a sub-popula-
tion of highly activated neutrophils primed for adhe-
sion, phagocytosis and enhanced production of reactive 
oxygen species. Recent studies suggest that oligosaccha-
rides containing sialyl Lex or its stereoisomer sialyl Lea, 
which resemble the P-selectin ligand, inhibit the binding 
of selectin ligands to the surface of endothelial cells and 
platelets; this interferes with the formation of PNC, 
the eﬀ ect of which is anti-inﬂ ammatory. The following 
oligosaccharide fractions were tested in vitro to establish 
whether they reduce leukocyte deceleration on U937 
cells, which express the P-selectin ligand: total human 
milk oligosaccharides, neutral oligosaccharides, total 
acidic oligosaccharides, neutral oligosaccharides with a 
polymerization degree of 4, fucosylated oligosaccharides 
and disialyl lacto-N-tetraose. The acidic oligosaccharide 
fraction produced a slight but deﬁ nite reduction of 
P-selectin ligand binding, similar to that of standard 
sialyl Lex, whereas the total neutral oligosaccharides 
and neutral fucosylated oligosaccharides fractions did 
not (Schumacher et al., 2006). These results support the 
notion of anti-inﬂ ammatory eﬀ ects of acidic human milk 
oligosaccharides.
MILK OLIGOSACCHARIDES OF THE COW AND 
OTHER DOMESTIC FARM ANIMALS AND THEIR 
UTILIZATION IN THE FUTURE INDUSTRY 
Nakamura et al. (2003) and Gopal & Gill (2000) 
stated that bovine colostrum collected immediately after 
parturition contains more than 1 g/L of oligosaccharides, 
but the mature milk contains only small amounts. 
Although 25 bovine oligosaccharides structures isolated 
from the colostrum have been completely characterized 
(Table 2), as many as 39 oligosaccharides have been de-
tected using a combination of nanoelectrospray Fourier 
transform ion cyclotron resonance (nESI-FTICR) mass 
spectrometry and matrix-assisted laser desorption/
ionization Fourier transform ion cyclotron resonance 
(MALDI-FTICR) mass spectrometry (Tao et al., 2008). 
Some bovine oligosaccharides include those that have N-
acetyllactosamine (Gal(β1-4)GlcNAc) instead of lactose 
at their reducing ends, such as free N-acetyllactosamine 
or 6’-N-acetylneuraminyl-N-acetyllactosamine (6’-SLN, 
Neu5Ac(α2-6)Gal(β1-4)GlcNAc) and others. There is 
a diﬀ erence in this respect between bovine and human 
milk oligosaccharides, insofar as almost all HMO con-
tain a lactose unit at their reducing ends.
Most of the acidic oligosaccharide fraction of bo-
vine colostrum consists of 3’-SL, 6’-SL, 6’-SLN and DSL 
(Neu5Ac(α2-8)Neu5Ac(α2-3)Gal(β1-4)Glc), with 3’-SL 
constituting 70% of this total (Tao et al., 2008). There is a 
diﬀ erence between human and cow in the ratio of 3’-SL 
to 6’-SL, in that 6’-SL predominates over 3’-SL in human 
milk/colostrum. The levels of the acidic oligosaccharides 
were maximal immediately after parturition, rapidly 
decreasing by 48 h post-partum (Nakamura et al., 2003). 
Since bovine colostrum contains some oligosaccha-
rides, which are mainly acidic, and mature bovine milk 
also contains them, although at lower concentrations, 
it can be expected that oligosaccharides derived from 
bovine colostrum or mature milk will be utilized by 
industry as functional foods, animal feeds or biomedical 
products. For example, several reports have suggested 
that bovine milk oligosaccharides can be used as anti 
infection materials.
It is thought that adhesion of Neisseria meningitides, 
a human-speciﬁ c pathogen causing meningitis and 
speticemia, is mediated by type IV pili (Hakkarainen et 
al., 2005). A mictotiter well pili-binding assay was used 
Table 2. Bovine milk oligosaccharides
No.     Oligosaccharide
Neutral oligosaccharides
Structure
1 N-Acetylgalactosaminylglucose
GalNAc( 1-4)Glc
2 LacNAc Gal( 1-4)GlcNAc
3 Lex trisaccharide Gal( 1-4)GlcNAc
4 3'-GalNAcL GalNAc( 1-3)Gal( 1-4)Glc
Fuc( 1-3)
5 Isoglobotriose Gal( 1-3)Gal( 1-4)Glc
6 3'-GL Gal( 1-3)Gal( 1-4)Glc
7 4'-GL Gal( 1-4)Gal( 1-4)Glc
8 6'-GL Gal( 1-6)Gal( 1-4)Glc
novo-LNP I9 Gal( 1-4)GlcNAc( 1-6)
Gal( 1-4)Glc
Gal( 1-3)
10 3'-GalNAcL GalNAc( 1-3)Gal( 1-4)Glc
Acidic oligosaccharides
14 3'-O-Lac phosphate Gal( 1-4)Glc-3'-PO4
15 3'S Gal Neu5Ac( 2-3)Gal
16 3'-SL Neu5Ac( 2-3)Gal( 1-4)Glc
17 6'-SL Neu5Ac( 2-6)Gal( 1-4)Glc
18 3'-Neu5GcL Neu5Gc( 2-3)Gal( 1-4)Glc
19 6'-Neu5GcL Neu5Gc( 2-6)Gal( 1-4)Glc
20 6'-SLacNAc Neu5Ac( 2-6)Gal( 1-4)GlcNAc
21 6'-Neu5GcLacNAc Neu5Gc( 2-6)Gal( 1-4)GlcNAc
11 6'-GlcNAcL GlcNAc( 1-6)Gal( 1-4)Glc
12 LNnT Gal( 1-4)GlcNAc( 1-3)Gal( 1-4)Glc
13 LNnH Gal( 1-4)GlcNAc( 1-6)
Gal( 1-4)GlcNAc( 1-3)
Gal( 1-4)Glc
22
23 DSL
24 6'-SLacNAc-1-O-phosphate
25 6'-SLacNAc-6-O-phosphate
Neu5Ac( 2-3)Gal(1-3)Gal(1-4)Glc
Neu5Ac( 2-8)Neu5Ac( 2-3)Gal( 1-4)Glc
Neu5Ac( 2-6)Gal( 1-4)GlcNAc-1-PO4
Neu5Ac( 2-6)Gal( 1-4)GlcNAc-6-PO4
-
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to investigate the binding of type IV pili isolated from N. 
meningitides to diﬀ erent glycoproteins. Inhibition of pili 
binding to bovine thyroglobulin and human salivary ag-
glutinin by fractionated human and bovine milk oligo-
saccharides was demonstrated. The binding of Neisseria 
pili to bovine thyroglobulin was more eﬀ ective and 
was clearly inhibited by neutral or acidic bovine milk 
oligosaccharides at concentrations of 1~2 g/l, suggesting 
that these fractions had the potential ability to inhibit 
the aĴ achment of this bacterium to the colonic mucosa 
(Hakkarainen et al., 2005).
Fractions containing milk oligosaccharides, in the 
form of supernatants that had been separated from co-
lostrum and from transitional, mature and late lactation 
milk of Spanish brown cows by ethanol precipitation 
and subsequent centrifugation, were used to investigate 
the inhibition of hemagglutination by seven enterotoxi-
genic E. coli strains (K99, FK, F41, F17, B16, B23 and B64). 
These strains had been isolated from diarrheal calves. 
The fractions from the transitional and mature milk in-
hibited hemagglutination by all of these strains, whereas 
those from colostrum and late lactation milk produced 
weaker inhibition (Martin et al., 2002). It was suggested 
that this inhibition was due to 3’-SL, 6’-SL, 6’-SLN and 
DSL. The fractions from transitional and mature milk, in 
which the ratio of 6’-SL to 3’-SL was higher than in the 
fractions from colostrum and late lactation milk, had a 
stronger eﬀ ect than the others
It can be expected that milk oligosaccharides of 
other domestic farm animals, such as goats, sheep, and 
camels, will also be used as biofunctional materials. The 
milk oligosaccharide content of goat milk is 0.25~0.39 
g/l; this is higher than that of bovine (0.03~0.06 g/l) or 
ovine (0.02~0.04 g/l) milk. In addition, the variety of 
oligosaccharides in goat milk is greater than that in 
bovine or ovine milk, as shown by the proﬁ les from 
HPEAC analysis (Martinez-Ferez et al., 2006; Mehra 
& Kelly, 2006). Colostrum from the Japanese Saanen 
breed contains more 6’-SL than 3’-SL; it also contains 
6’-N-glycolylneuraminyllactose (Neu5Gc(α2-6)Gal(β1-
4)Glc), Gal(α1-3)Gal(β1-4)Glc, Gal(β1-3)Gal(β1-4)Glc, 
Gal(β1-6)Gal(β1-4)Glc and 2’-FL (Urashima et al., 1994, 
1997). Another study has shown that mature milk from 
Spanish goats contains 6’-SL, 3’-SL, disialyllactose, N-
glycolylneuraminyllactose, 3’-galactosyllactose, N-acetyl 
glucosaminyllactose, LNH and additional high molecu-
lar oligosaccharides, as demonstrated by analysis with 
FAB-MS, but no fucosyl oligosaccharides (Martinez-
Ferez et al., 2006). Ovine colostrum contains more 
3’-N-glycolylneuraminyllactose than 3’-SL and 6’-SL 
(Nakamura et al., 1998) and, notably, contains Neu5Gc 
in preference to Neu5Ac. 
A recent study on rats showed that goat milk oligo-
saccharides have an anti-inﬂ ammatory eﬀ ect in the colon 
(Daddaowa et al., 2006). In this study, colitis was induced 
by the hapten, trinitrobenzenesulfonic acid (TNBS). The 
experimental rats (OS) were fed a diet containing 500 
mg/kg per day of goat milk oligosaccharides, from 2 
days prior to the induction until day 6, after which all 
the rats were weighed and then killed, the entire colon 
was removed, opened and scored for visible damage 
and then divided into several pieces for biochemical 
determinations. When the OS rats were compared with 
control rats in which colitis had been induced by TNBS 
but that had not been treated with oligosaccharides, it 
was found that the OS rats showed decreased anorexia, 
reduced loss of body weight, reduced bowel wall thick-
ening and less necrosis of the colon. Biochemically, the 
OS rats had lower colonic levels of inducible nitric oxide 
synthase (iNOS), cyclooxygenase 2 (COX2), interleukin-
1β and mucin 3, as well as increased trefoil factor 3. 
These results showed that goat milk oligosaccharides 
are anti-inﬂ ammatory when administered as a pretreat-
ment in the TNBS model of rat colitis, most likely due to 
their action as prebiotics resulting in favorable changes 
in the colonic bacterial ﬂ ora. Since TNBS-induced 
colitis is widely used as a preclinical model of inﬂ am-
matory bowel disease in humans, it was suggested that 
goat milk oligosaccharides might be useful in the man-
agement of this disease.  
CONCLUDING REMARKS
As the development and improvement of methods 
for structural determination by using smaller amount 
of samples as presently required still going on, the 
new structure of milk oligosaccharides will be still 
discovered. More studies on the functional biological 
characteristics of the milk oligosaccharides are still 
needed.  Those study results are needed to conﬁ rm milk 
oligosaccharides role in the various biological processes, 
as well as to overcome the problems especially in the 
synthesis of milk oligosaccharides-like compound at the 
industrial level. The isolation of milk oligosaccharides 
from the colostrum of domestic animals at industrial 
scale, for their utilization as biofunctional food and 
feedstuﬀ s as well as for drugs is still in the early stage. 
Although still in its infancy, milk oligosaccharides 
industrial utilization can be expected in the near future.
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